127 related articles for article (PubMed ID: 11007696)
1. Ace inhibitors and erythropoietin response in hemodialysis patients.
Ertürk S
Am J Kidney Dis; 2000 Oct; 36(4):880. PubMed ID: 11007696
[No Abstract] [Full Text] [Related]
2. ACE inhibitors do not induce recombinant human erythropoietin resistance in hemodialysis patients.
Abu-Alfa AK; Cruz D; Perazella MA; Mahnensmith RL; Simon D; Bia MJ
Am J Kidney Dis; 2000 Jun; 35(6):1076-82. PubMed ID: 10845820
[TBL] [Abstract][Full Text] [Related]
3. The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.
Macdougall IC
Nephrol Dial Transplant; 1999 Aug; 14(8):1836-41. PubMed ID: 10462256
[No Abstract] [Full Text] [Related]
4. Oral ascorbic acid as adjuvant to epoetin alfa in hemodialysis patients with hyperferritinemia.
Nguyen TV
Am J Health Syst Pharm; 2004 Oct; 61(19):2007-8. PubMed ID: 15509119
[No Abstract] [Full Text] [Related]
5. Use of epoetin in chronic renal failure.
Coyne DW
JAMA; 2007 Apr; 297(15):1713-6. PubMed ID: 17440149
[No Abstract] [Full Text] [Related]
6. Epoetin dosing and dialysis facility ownership.
Kliger AS; Nissenson AR
JAMA; 2007 Aug; 298(8):861-2; author reply 862-3. PubMed ID: 17712067
[No Abstract] [Full Text] [Related]
7. Angiotensin-converting enzyme inhibitor therapy in chronic hemodialysis patients: any evidence of erythropoietin resistance?
Cruz DN; Perazella MA; Abu-Alfa AK; Mahnensmith RL
Am J Kidney Dis; 1996 Oct; 28(4):535-40. PubMed ID: 8840943
[TBL] [Abstract][Full Text] [Related]
8. Use of Carnitor for Epogen resistant anemia.
Simard JC
ANNA J; 1999 Feb; 26(1):41-2. PubMed ID: 10222857
[TBL] [Abstract][Full Text] [Related]
9. Epoetin dosing and dialysis facility ownership.
Regidor DL; Kalantar-Zadeh K; Kovesdy CP
JAMA; 2007 Aug; 298(8):862; author reply 862-3. PubMed ID: 17712068
[No Abstract] [Full Text] [Related]
10. Anemia management in chronic kidney disease: role of factors affecting epoetin responsiveness.
Eschbach JW
J Am Soc Nephrol; 2002 May; 13(5):1412-4. PubMed ID: 11961032
[No Abstract] [Full Text] [Related]
11. Potential angiotensin-converting enzyme inhibitor-epoetin alfa interaction in patients receiving chronic hemodialysis.
Schwenk MH; Jumani AQ; Rosenberg CR; Kulogowski JE; Charytan C; Spinowitz BS
Pharmacotherapy; 1998; 18(3):627-30. PubMed ID: 9620114
[TBL] [Abstract][Full Text] [Related]
12. Longer-term outcomes of darbepoetin alfa versus epoetin alfa in patients with ESRD initiating hemodialysis: a quasi-experimental cohort study.
Winkelmayer WC; Chang TI; Mitani AA; Wilhelm-Leen ER; Ding V; Chertow GM; Brookhart MA; Goldstein BA
Am J Kidney Dis; 2015 Jul; 66(1):106-13. PubMed ID: 25943715
[TBL] [Abstract][Full Text] [Related]
13. Comment on "Does ferric gluconate lower epoetin requirements in hemodialysis patients with high ferritin levels?".
Coyne DW; Trout JR; Kapoian T
Nat Clin Pract Nephrol; 2008 Oct; 4(10):E1; discussion E2. PubMed ID: 18818660
[No Abstract] [Full Text] [Related]
14. Effectiveness of a pharmacist-implemented anemia management protocol in an outpatient hemodialysis unit.
To LL; Stoner CP; Stolley SN; Buenviaje JD; Ziegler TW
Am J Health Syst Pharm; 2001 Nov; 58(21):2061-5. PubMed ID: 11715828
[No Abstract] [Full Text] [Related]
15. Comparison of the therapeutic effects of epoetin zeta to epoetin alfa in the maintenance phase of renal anaemia treatment.
Wizemann V; Rutkowski B; Baldamus C; Scigalla P; Koytchev R;
Curr Med Res Opin; 2008 Mar; 24(3):625-37. PubMed ID: 18208642
[TBL] [Abstract][Full Text] [Related]
16. Effects of Epoetin alfa on hemostasis in chronic renal failure.
Tang WW; Stead RA; Goodkin DA
Am J Nephrol; 1998; 18(4):263-73. PubMed ID: 9653828
[TBL] [Abstract][Full Text] [Related]
17. Resource utilisation and time commitment associated with correction of anaemia in cancer patients using epoetin alfa.
Lynch DM; Slaven T
Clin Drug Investig; 2007; 27(9):661-2. PubMed ID: 17705574
[No Abstract] [Full Text] [Related]
18. Regarding impact of epoetin alfa on clinical end points in patients with chronic renal failure: a meta-analysis.
Tonelli M; Owen WF; Jindal K; Winkelmayer WC; Manns B
Kidney Int; 2004 Oct; 66(4):1712; author reply 1712-3. PubMed ID: 15458473
[No Abstract] [Full Text] [Related]
19. Switching epoetin alfa and epoetin zeta in patients with renal anemia on dialysis: Posthoc analysis.
Więcek A; Ahmed I; Scigalla P; Koytchev R
Adv Ther; 2010 Dec; 27(12):941-52. PubMed ID: 20972656
[TBL] [Abstract][Full Text] [Related]
20. Epoetin alfa resistance in hemodialysis patients with chronic kidney disease: a longitudinal study.
Santos EJF; Hortegal EV; Serra HO; Lages JS; Salgado-Filho N; Dos Santos AM
Braz J Med Biol Res; 2018; 51(7):e7288. PubMed ID: 29742267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
